Database

Startups

Main Industry
Health Care
Founded Year
2014
Unified Business No.
54737528
Status
Active
Number of Employees
0
Total Paid-in Capital
160,000,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.

Similar Companies

TAIRX, INC.

1. CVM-1118 (Foslinanib)
2. ZelniteR
3. TRX-NOC
4. TRX-920
5. TRX-105

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

XANTHO BIOTECHNOLOGY CO., LTD.

*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs. It is anticipated that the results of the Phase IIa clinical study will be available in Q2 2025.